Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 433

1.

Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB; Platinum Study Group.

J Clin Oncol. 2018 May 20;36(15):1505-1512. doi: 10.1200/JCO.2017.77.0735. Epub 2018 Apr 4.

PMID:
29617189
2.

Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.

Feldman DR, Ardeshir-Rouhani-Fard S, Monahan P, Sesso HD, Fung C, Williams AM, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Zaid MA, Lipshultz SE, Einhorn LH, Oeffinger KC, Travis LB, Fossa SD; Platinum Study Group.

Clin Genitourin Cancer. 2018 Feb 5. pii: S1558-7673(18)30070-3. doi: 10.1016/j.clgc.2018.01.011. [Epub ahead of print]

PMID:
29534941
3.

Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.

Zaid MA, Gathirua-Mwangi WG, Fung C, Monahan PO, El-Charif O, Williams AM, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse SK, Ardeshir-Rouhani-Fard S, Dinh PC Jr, Sesso HD, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Natl Compr Canc Netw. 2018 Mar;16(3):257-265. doi: 10.6004/jnccn.2017.7046.

PMID:
29523664
4.

Coping Skills Practice and Symptom Change: A Secondary Analysis of a Pilot Telephone Symptom Management Intervention for Lung Cancer Patients and Their Family Caregivers.

Winger JG, Rand KL, Hanna N, Jalal SI, Einhorn LH, Birdas TJ, Ceppa DP, Kesler KA, Champion VL, Mosher CE.

J Pain Symptom Manage. 2018 May;55(5):1341-1349.e4. doi: 10.1016/j.jpainsymman.2018.01.005. Epub 2018 Jan 31.

PMID:
29366911
5.

Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?

Cheng M, Durm G, Hanna N, Einhorn LH, Kong FS.

Future Oncol. 2017 Dec;13(28):2503-2505. doi: 10.2217/fon-2017-0405. Epub 2017 Nov 23. No abstract available.

6.

Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.

Albany C, Adra N, Snavely AC, Cary C, Masterson TA, Foster RS, Kesler K, Ulbright TM, Cheng L, Chovanec M, Taza F, Ku K, Brames MJ, Hanna NH, Einhorn LH.

Ann Oncol. 2018 Feb 1;29(2):341-346. doi: 10.1093/annonc/mdx731.

PMID:
29140422
7.

Salvage therapy for relapsed testicular cancer.

Adra N, Einhorn LH.

Oncotarget. 2017 Sep 14;8(45):78253-78254. doi: 10.18632/oncotarget.20872. eCollection 2017 Oct 3. No abstract available.

8.

Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution.

Cary C, Jacob JM, Albany C, Masterson TA, Hanna NH, Einhorn LH, Foster RS.

Clin Genitourin Cancer. 2018 Apr;16(2):e307-e313. doi: 10.1016/j.clgc.2017.10.008. Epub 2017 Oct 16.

PMID:
29104087
9.

Salvage therapy for relapsed testicular cancer.

Adra N, Einhorn LH.

Oncotarget. 2017 Aug 25;8(41):69200-69201. doi: 10.18632/oncotarget.20573. eCollection 2017 Sep 19. No abstract available.

10.

Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.

Adra N, Einhorn LH, Althouse SK, Ammakkanavar NR, Musapatika D, Albany C, Vaughn D, Hanna NH.

Ann Oncol. 2018 Jan 1;29(1):209-214. doi: 10.1093/annonc/mdx680.

PMID:
29045540
11.

Long-term toxicity of cisplatin in germ-cell tumor survivors.

Chovanec M, Abu Zaid M, Hanna N, El-Kouri N, Einhorn LH, Albany C.

Ann Oncol. 2017 Nov 1;28(11):2670-2679. doi: 10.1093/annonc/mdx360. Review.

PMID:
29045502
12.

Love in the Time of Cancer.

Einhorn LH.

J Clin Oncol. 2017 Oct 20;35(30):3482-3483. doi: 10.1200/JCO.2017.73.9755. Epub 2017 Aug 16. No abstract available.

PMID:
28813165
13.

Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimens.

Harari SE, Sassoon DJ, Priemer DS, Jacob JM, Eble JN, Caliò A, Grignon DJ, Idrees M, Albany C, Masterson TA, Hanna NH, Foster RS, Ulbright TM, Einhorn LH, Cheng L.

Urol Oncol. 2017 Oct;35(10):605.e9-605.e16. doi: 10.1016/j.urolonc.2017.05.018. Epub 2017 Jun 21. Review.

PMID:
28647396
14.

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.

Dolan ME, El Charif O, Wheeler HE, Gamazon ER, Ardeshir-Rouhani-Fard S, Monahan P, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kim J, Fossa SD, Hertz DL, Mushiroda T, Kubo M, Einhorn LH, Cox NJ, Travis LB; Platinum Study Group.

Clin Cancer Res. 2017 Oct 1;23(19):5757-5768. doi: 10.1158/1078-0432.CCR-16-3224. Epub 2017 Jun 13.

PMID:
28611204
15.

Testicular cancer update.

Adra N, Einhorn LH.

Clin Adv Hematol Oncol. 2017 May;15(5):386-396. Review.

PMID:
28591093
16.

Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.

Fung C, Sesso HD, Williams AM, Kerns SL, Monahan P, Abu Zaid M, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Kollmannsberger CK, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Lipshultz SE, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Clin Oncol. 2017 Apr 10;35(11):1211-1222. doi: 10.1200/JCO.2016.70.3108. Epub 2017 Feb 27.

17.

Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity.

Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Mapes B, Fossa SD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kollmannsberger C, Kim J, Mushiroda T, Kubo M, Ardeshir-Rouhani-Fard S, Einhorn LH, Cox NJ, Dolan ME, Travis LB.

Clin Cancer Res. 2017 Jul 1;23(13):3325-3333. doi: 10.1158/1078-0432.CCR-16-2809. Epub 2016 Dec 30.

18.

Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.

Albany C, Hever-Jardine MP, von Herrmann KM, Yim CY, Tam J, Warzecha JM, Shin L, Bock SE, Curran BS, Chaudhry AS, Kim F, Sandusky GE, Taverna P, Freemantle SJ, Christensen BC, Einhorn LH, Spinella MJ.

Oncotarget. 2017 Jan 10;8(2):2949-2959. doi: 10.18632/oncotarget.13811.

19.

High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience.

Adra N, Abonour R, Althouse SK, Albany C, Hanna NH, Einhorn LH.

J Clin Oncol. 2017 Apr 1;35(10):1096-1102. doi: 10.1200/JCO.2016.69.5395. Epub 2016 Nov 21.

20.

2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ.

Support Care Cancer. 2017 Jan;25(1):303-308. Epub 2016 Nov 4.

PMID:
27815710
21.

Randomized Pilot Trial of a Telephone Symptom Management Intervention for Symptomatic Lung Cancer Patients and Their Family Caregivers.

Mosher CE, Winger JG, Hanna N, Jalal SI, Einhorn LH, Birdas TJ, Ceppa DP, Kesler KA, Schmitt J, Kashy DA, Champion VL.

J Pain Symptom Manage. 2016 Oct;52(4):469-482. doi: 10.1016/j.jpainsymman.2016.04.006. Epub 2016 Jul 9.

22.

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015.

Ann Oncol. 2016 Sep;27(suppl 5):v119-v133. No abstract available.

PMID:
27664248
23.

Perioperative Morbidity and Mortality Associated With Bleomycin in Primary Mediastinal Nonseminomatous Germ Cell Tumor.

Ranganath P, Kesler KA, Einhorn LH.

J Clin Oncol. 2016 Dec 20;34(36):4445-4446. doi: 10.1200/JCO.2016.69.8910. Epub 2016 Sep 30. No abstract available.

PMID:
27621392
24.

A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.

Necchi A, Pond GR, Nicolai N, Giannatempo P, Raggi D, Adra N, Hanna NH, Salvioni R, Einhorn LH, Albany C.

Clin Genitourin Cancer. 2017 Apr;15(2):306-312.e3. doi: 10.1016/j.clgc.2016.07.022. Epub 2016 Aug 8.

PMID:
27594554
25.

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.

Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, Ferguson ME, Jiang G, Ammakkanavar NR, Einhorn LH, Cheng L, Nassiri M, Davidson DD, Rushing DA, Loehrer PJ, Pili R, Hanna N, Callaghan JT, Skaar TC, Helft PR, Shahda S, O'Neil BH, Schneider BP.

Oncotarget. 2016 Aug 30;7(35):56491-56500. doi: 10.18632/oncotarget.10606.

26.

Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.

Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Budnick A, Johnson EM, Ardeshir-Rouhani-Fard S, Einhorn LH, Lipshultz SE, Dolan ME, Travis LB.

J Clin Oncol. 2016 Aug 10;34(23):2712-20. doi: 10.1200/JCO.2016.66.8822. Epub 2016 Jun 27.

27.

Salvage Therapy for Patients With Germ Cell Tumor.

Rashdan S, Einhorn LH.

J Oncol Pract. 2016 May;12(5):437-43. doi: 10.1200/JOP.2016.011411.

PMID:
27170693
28.

Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.

Adra N, Althouse SK, Liu H, Brames MJ, Hanna NH, Einhorn LH, Albany C.

Ann Oncol. 2016 May;27(5):875-9. doi: 10.1093/annonc/mdw045. Epub 2016 Feb 9.

29.

Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.

Adra N, Albany C, Brames MJ, Case-Eads S, Johnson CS, Liu Z, Fausel CA, Breen T, Hanna NH, Hauke RJ, Picus J, Einhorn LH.

Support Care Cancer. 2016 Jul;24(7):2837-42. doi: 10.1007/s00520-016-3100-y. Epub 2016 Feb 2.

30.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.

31.

Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration.

Giannatempo P, Pond GR, Sonpavde G, Albany C, Loriot Y, Sweeney CJ, Salvioni R, Colecchia M, Nicolai N, Raggi D, Rice KR, Flack CK, El Mouallem NR, Feldman H, Fizazi K, Einhorn LH, Foster RS, Necchi A, Cary C.

J Urol. 2016 Jul;196(1):95-100. doi: 10.1016/j.juro.2015.12.082. Epub 2015 Dec 31.

PMID:
26748165
32.

Chemotherapy-Related Chronic Myelogenous Leukemia: A Case Series of Patients With Germ Cell Tumor.

Adra N, Sayar H, Einhorn LH.

JAMA Oncol. 2016 Mar;2(3):391-2. doi: 10.1001/jamaoncol.2015.4837. No abstract available.

33.

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.

Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, Necchi A, Flechon A, Boyle H, Chung P, Huddart RA, Bokemeyer C, Tryakin A, Sava T, Winquist EW, De Giorgi U, Aparicio J, Sweeney CJ, Cohn Cedermark G, Beyer J, Powles T.

J Clin Oncol. 2016 Feb 1;34(4):345-51. doi: 10.1200/JCO.2015.62.7000. Epub 2015 Oct 12.

34.

Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation.

Cary C, Pedrosa JA, Jacob J, Beck SD, Rice KR, Einhorn LH, Foster RS.

Cancer. 2015 Dec 15;121(24):4369-75. doi: 10.1002/cncr.29678. Epub 2015 Sep 15.

35.

Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.

Mulherin BP, Brames MJ, Einhorn LH.

Am J Clin Oncol. 2015 Aug;38(4):373-6. doi: 10.1097/COC.0b013e31829e19e0.

PMID:
26214082
36.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

37.

Salvage therapy in patients with germ cell tumors.

Einhorn LH.

Am Soc Clin Oncol Educ Book. 2015:e259-61. doi: 10.14694/EdBook_AM.2015.35.e259.

38.

Utilization of sperm banking and barriers to its use in testicular cancer patients.

Sonnenburg DW, Brames MJ, Case-Eads S, Einhorn LH.

Support Care Cancer. 2015 Sep;23(9):2763-8. doi: 10.1007/s00520-015-2641-9. Epub 2015 Feb 15.

PMID:
25680764
39.

High-dose chemotherapy for recurrent ovarian germ cell tumors.

Reddy Ammakkanavar N, Matei D, Abonour R, Einhorn LH.

J Clin Oncol. 2015 Jan 10;33(2):226-7. doi: 10.1200/JCO.2014.59.4325. Epub 2014 Dec 1. No abstract available.

PMID:
25452440
40.

Testicular cancer--discoveries and updates.

Hanna NH, Einhorn LH.

N Engl J Med. 2014 Nov 20;371(21):2005-16. doi: 10.1056/NEJMra1407550. Review. No abstract available. Erratum in: N Engl J Med. 2014 Dec 11;371(24):2342.

PMID:
25409373
41.

Surgical management of late relapse on surveillance in patients presenting with clinical stage I testicular cancer.

Rice KR, Beck SD, Pedrosa JA, Masterson TA, Einhorn LH, Foster RS.

Urology. 2014 Oct;84(4):886-90. doi: 10.1016/j.urology.2014.05.054.

PMID:
25260450
42.

The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.

Cary KC, Pedrosa JA, Kaimakliotis HZ, Masterson TA, Einhorn LH, Foster RS.

J Urol. 2015 Feb;193(2):507-12. doi: 10.1016/j.juro.2014.09.090. Epub 2014 Sep 22.

PMID:
25254937
43.

Testicular cancer: a reflection on 50 years of discovery.

Hanna N, Einhorn LH.

J Clin Oncol. 2014 Oct 1;32(28):3085-92. doi: 10.1200/JCO.2014.56.0896. Epub 2014 Jul 14. No abstract available.

PMID:
25024068
44.

Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes.

Rice KR, Magers MJ, Beck SD, Cary KC, Einhorn LH, Ulbright TM, Foster RS.

J Urol. 2014 Nov;192(5):1403-9. doi: 10.1016/j.juro.2014.05.118. Epub 2014 Jun 18.

PMID:
24952240
45.

"Somatic-type" malignancies arising from testicular germ cell tumors: a clinicopathologic study of 124 cases with emphasis on glandular tumors supporting frequent yolk sac tumor origin.

Magers MJ, Kao CS, Cole CD, Rice KR, Foster RS, Einhorn LH, Ulbright TM.

Am J Surg Pathol. 2014 Oct;38(10):1396-409. doi: 10.1097/PAS.0000000000000262.

PMID:
24921638
46.

Very late relapse of germ cell tumor as a teratoma: a case report and review of the literature.

Arafat W, Albany C, Ulbright TM, Foster R, Einhorn LH.

J Surg Case Rep. 2014 Jun 2;2014(6). pii: rju051. doi: 10.1093/jscr/rju051.

47.

Survival analysis of pure seminoma at post-chemotherapy retroperitoneal lymph node dissection.

Rice KR, Beck SD, Bihrle R, Cary KC, Einhorn LH, Foster RS.

J Urol. 2014 Nov;192(5):1397-402. doi: 10.1016/j.juro.2014.04.097. Epub 2014 May 9.

PMID:
24813309
48.

Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME; Platinum Study Group.

J Natl Cancer Inst. 2014 Mar 12;106(5). pii: dju044. doi: 10.1093/jnci/dju044. Review.

49.

Barriers to mental health service use and preferences for addressing emotional concerns among lung cancer patients.

Mosher CE, Winger JG, Hanna N, Jalal SI, Fakiris AJ, Einhorn LH, Birdas TJ, Kesler KA, Champion VL.

Psychooncology. 2014 Jul;23(7):812-9. doi: 10.1002/pon.3488. Epub 2014 Feb 3.

50.

Why oncologists should support single-payer national health insurance.

Drasga RE, Einhorn LH.

J Oncol Pract. 2014 Jan;10(1):7-11. doi: 10.1200/JOP.2013.001160. No abstract available.

PMID:
24443728

Supplemental Content

Loading ...
Support Center